Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.54 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.54 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | BHMT | Q93088 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968570 | 1.00 | CACNA2D1 (0.54) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3783223 | 0.97 | CACNA2D1 (0.52) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| Ammonia Solution, Strong SCHEMBL28027924 | 0.97 | CACNA2D1 (0.52) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL2171052 | 0.95 | CACNA2D1 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL14359978 | 0.88 | CACNA2D1 (0.46) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL2844937 | 0.85 | CACNA2D1 (0.63) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL28709775 | 0.85 | CACNA2D1 (0.42) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL258152 | 0.82 | SLC22A6 (0.50) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL9562929 | 0.82 | CACNA2D1 (0.40) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL27985207 | 0.82 | FOLH1 (0.41) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
| EP-1806342-B1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| EP-1841726-B1 | AN ASYMMETRIC SYNTHESIS OF (S)-(+)-3-(AMINOMETHYL)-5-METHYLHEXANOIC ACID | TEVA PHARMA (IL) | 2012-10-31 | — | — | EP | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| EP-1572173-B1 | ALPHA-2-DELTA LIGAND TO TREAT LOWER URINARY TRACT SYMPTOMS | WARNER LAMBERT CO (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009001372-A2 | A NOVEL PROCESS FOR THE PREPARATION OF PREGABALIN | SATYANARAYANA REDDY MANNE (IN) | 2008-12-31 | — | — | WO | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| WO-2007143113-A2 | THE USE OF ENZYMATIC RESOLUTION FOR THE PREPARATION OF INTERMEDIATES OF PREGABALIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-13 | — | — | WO | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | CACNA2D1 450/4885CACNB3 852/4885CACNA1C 696/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | CACNA2D1 681/4885CACNB3 739/4885CACNA1C 590/4885 |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | CACNA2D1 3895/4885CACNB3 2520/4885CACNA1C 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.